Dashboard
Manage Tickers

LPCN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
08/20/2025 13:11:10

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

correction-lipocine-q2-eps-041-misses-040-estimate-sales-622849k-beat-229000k-estimate
CORRECTION: Lipocine Q2 EPS $(0.41) Misses...
08/05/2025 14:11:02

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by...

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
06/27/2025 15:25:51

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

lipocine-doses-first-patient-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression
Lipocine Doses First Patient In Phase 3 Tr...
06/26/2025 12:08:33

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
06/10/2025 11:00:38

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

lipocine-says-licensing-partner-verity-pharma-files-new-drug-submission-for-tlando-in-canada
Lipocine Says Licensing Partner, Verity Ph...
06/09/2025 12:01:53

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually fo...

lipocine-shareholders-approved-amendment-to-cut-authorized-common-stock-from-200m-to-75m-shares-at-annual-meeting-held-on-june-4-2025
Lipocine Shareholders Approved Amendment t...
06/09/2025 11:46:06

lipocines-licensing-partner-verity-pharma-filed-a-new-drug-submission-for-tlando-in-canada-tlando-is-the-first-and-only-oral-testosterone-replacement-therapy-option-approved-by-fdathat-does-not-require-dose-titration
Lipocine's Licensing Partner, Verity Pharm...
06/09/2025 10:25:27

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually fo...

hc-wainwright--co-assumes-lipocine-at-buy-announces-price-target-of-8
HC Wainwright & Co. Assumes Lipocine at Bu...
05/29/2025 14:46:45

HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $8.

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
05/19/2025 12:09:34

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
05/12/2025 17:07:15

lipocine-q1-eps-035-beats-041-estimate-sales-9386k-miss-37000k-estimate
Lipocine Q1 EPS $(0.35) Beats $(0.41) Esti...
05/08/2025 12:10:05

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 1...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 21:06:18

lipocine-enters-into-license-and-supply-agreement-with-ach-laboratrios-farmacuitcos-sa-granting-exclusive-rights-to-market-tlando-in-brazil
Lipocine Enters Into License And Supply Ag...
05/06/2025 12:04:50

Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Ora...

lipocine-announces-initiation-of-a-phase-3-trial-for-lpcn-1154-which-is-in-development-for-treatment-of-postpartum-depression
Lipocine Announces Initiation Of A Phase 3...
03/26/2025 12:06:13

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective ora...

lipocine-fy24-sales-11198m-beat-10321m-estimate
Lipocine FY24 Sales $11.198M Beat $10.321M...
03/13/2025 12:09:37

lipocine-announces-revised-fda-guidance-for-lpcn-1154-requiring-efficacy-and-safety-study-for-postpartum-depression-nda-submission
Lipocine Announces Revised FDA Guidance Fo...
02/06/2025 13:04:27

fda-grants-fast-track-designation-to-lipocines-lpcn-1148-for-treating-sarcopenia-in-patients-with-decompensated-cirrhosis-targeting-first-in-class-status-with-novel-mechanism-of-action
FDA Grants Fast Track Designation To Lipoc...
12/17/2024 13:02:18

lipocine-announces-the-publication-and-discussion-of-a-manuscript-oral-lpcn-1148-improves-sarcopenia-and-hepatic-encephalopathy-in-male-patients-with-cirrhosis-a-randomized-placebo-controlled-phase-2-trial-in-the-journal-hepatology-and-discussion-at-the-liver-meeting-2024-editors-cut
Lipocine Announces The Publication And Dis...
11/18/2024 13:14:20

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics...

lipocine-q3-eps-044-beats-048-estimate
Lipocine Q3 EPS $(0.44) Beats $(0.48) Esti...
11/07/2024 13:09:27

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION